Regulatory adaptive status in determining the effectiveness of nebivololum and sotalolum in patients with hypertensive disease and paroxysmal atrial fibrillation

Abstract

Aim: compare the effectiveness of treatment with nebivololum or sotalolum in patients with hypertensive disease (HD) and paroxysmal atral fibrillation (AF) taking into account quantitative evaluation of the regulatory adaptive status (RAS). Materials and methods. 50 patients with HD of stages II-III and paroxysmal AF took part in the research, they were randomized into two groups for treatment with nebivololum (5.6±1.6 mg/day n=25) or sotalolum (157.0±38.3 mg/day, n=25). As part of combination therapy, patients were administered lisinoprilum (14.3±3.7 mg/day and 14.4±3.9 mg/day), when required alsoatorvastatinum (18.8±4.4 mg/day, n=11 and 16.0±5.1 mg/day, n=12), acetylsalicylic acid (91.2±14.1 mg/day, n=11and 92.1±16.8 mg/day, n=11), respectively. Initially and 6 months after therapy, the following was done: quantitative assessment of RAS (by cardio-respiratory synchronism test), echocardiography, triplex scanning of brachiocephalic arteries, treadmill test, six-minute walk test, all-day monitoring of blood pressure and electrocardiogram, subjective assessment of quality of life. Results. Both drug regimens comparably improved structural and functional condition of the heart, controlled arterial hypertension, effectively suppressed paroxysms of AF, improved the quality of life. At the same time, the use of nebivololum increased the RAS and increased exercise tolerance, to a lesser degree than the use of sotalolum. Conclusion. In patients with HD of stages II-III and paroxysmal AF the use of nebivololum as part of combination therapy may be preferable to sotalolum due to its positive impact on the RAS.

Keywords

• regulatory adaptive status
• hypertensive disease
• paroxysmal atrial fibrillation
• nebivololum
• sotalolum